Core Concepts
Paxlovid's effectiveness against COVID-19 variants has decreased in preventing hospitalization but remains highly effective in preventing death.
Abstract
The study published in JAMA Open Network compared the effectiveness of Pfizer's COVID-19 antiviral Paxlovid and Merck's antiviral Lagevrio in preventing hospitalization and death in high-risk patients. The real-world study analyzed electronic health records of 68,867 COVID patients and found that Paxlovid was 37% effective in preventing death or hospitalization compared to no treatment. However, when looking at death alone, Paxlovid was 84% effective. The study highlighted that the effectiveness of Paxlovid in real-world scenarios was lower than in clinical trials due to the evolution of the virus and the inclusion of vaccinated individuals. Both Paxlovid and Lagevrio are recommended for high-risk patients to reduce mortality and hospitalization, even with the presence of Omicron subvariants.
Stats
Paxlovid was about 37% effective at preventing death or hospitalization in high-risk patients compared to no treatment.
Paxlovid was about 84% effective in preventing death alone.
The effectiveness rate of Paxlovid in clinical trials in 2021 was about 86%.
Lagevrio was about 41% effective in preventing death or hospitalization.
Lagevrio was about 77% effective in preventing death alone.
Quotes
"These findings suggest that the use of either nirmatrelvir (Paxlovid) or molnupiravir (Lagevrio) is associated with reductions in mortality and hospitalization in patients infected with Omicron, regardless of age, race and ethnicity, virus strain, vaccination status, previous infection status, or coexisting conditions." - Study